Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
Status:
Terminated
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of high-dose rituximab combined with
temozolomide in the treatment of patients with Primary Central Nervous System Lymphomas
(PCNSL). This novel combination will be evaluated in PCNSL patients who are 60 years of age
or older, or in patients 18 years or older who refuse methotrexate-based treatment.